Cartner S C, Lindsey J R, Gibbs-Erwin J, Cassell G H, Simecka J W
Department of Comparative Medicine, Schools of Medicine and Dentistry, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA.
Infect Immun. 1998 Aug;66(8):3485-91. doi: 10.1128/IAI.66.8.3485-3491.1998.
Current evidence suggests that host defense in respiratory mycoplasmosis is dependent on both innate and humoral immunity. To further delineate the roles of innate and adaptive immunity in antimycoplasmal defenses, we intranasally infected C3H/HeSnJ-scid/scid (C3H-SCID), C3H/HeSnJ (C3H), C57BL/6J-scid/scid (C57-SCID), and C57BL/6N (C57BL) mice with Mycoplasma pulmonis and at 14 and 21 days postinfection performed quantitative cultures of lungs and spleens, quantification of lung lesions, and histopathologic assessments of all other major organs. We found that numbers of mycoplasmas in lungs were associated with genetic background (C3H susceptible, C57BL resistant) rather than functional state of adaptive immunity, indicating that innate immunity is the main contributor to antimycoplasmal defense of the lungs. Extrapulmonary dissemination of mycoplasmas with colonization of spleens and histologic lesions in multiple organs was a common occurrence in all mice. The absence of adaptive immune responses in severe combined immunodeficient (SCID) mice resulted in increased mycoplasmal colonization of spleens and lesions in extrapulmonary sites, particularly spleens, hearts, and joints, and also reduced lung lesion severity. The transfer of anti-M. pulmonis serum to infected C3H-SCID mice prevented extrapulmonary infection and disease, while the severity of lung lesions was restored by transfer of naive spleen cells to infected C3H-SCID mice. Collectively, our results strongly support the conclusions that innate immunity provides antimycoplasmal defense of the lungs and humoral immunity has the major role in defense against systemic dissemination of mycoplasmal infection, but cellular immune responses may be important in exacerbation of mycoplasmal lung disease.
目前的证据表明,呼吸道支原体感染中的宿主防御依赖于固有免疫和体液免疫。为了进一步阐明固有免疫和适应性免疫在抗支原体防御中的作用,我们经鼻用肺炎支原体感染了C3H/HeSnJ-scid/scid(C3H-SCID)、C3H/HeSnJ(C3H)、C57BL/6J-scid/scid(C57-SCID)和C57BL/6N(C57BL)小鼠,并在感染后14天和21天对肺和脾脏进行定量培养、对肺部病变进行定量分析以及对所有其他主要器官进行组织病理学评估。我们发现,肺中支原体的数量与遗传背景(C3H易感,C57BL抗性)相关,而非适应性免疫的功能状态,这表明固有免疫是肺部抗支原体防御的主要贡献者。支原体在肺外扩散并定植于脾脏以及在多个器官中出现组织学病变在所有小鼠中都很常见。严重联合免疫缺陷(SCID)小鼠缺乏适应性免疫反应导致脾脏支原体定植增加以及肺外部位,特别是脾脏、心脏和关节出现病变,同时肺部病变的严重程度也降低。将抗肺炎支原体血清转移至感染的C3H-SCID小鼠可预防肺外感染和疾病,而将未免疫的脾细胞转移至感染的C3H-SCID小鼠可恢复肺部病变的严重程度。总体而言,我们的结果有力地支持了以下结论:固有免疫为肺部提供抗支原体防御,体液免疫在抵御支原体感染的全身扩散中起主要作用,但细胞免疫反应可能在支原体性肺病的加重中起重要作用。